November 2024- Sysmex Corporation announced the first overseas surgery (robot-assisted radical prostatectomy) using the “hinotori™ Surgical Robot System” (hinotori™) was successfully performed at Singapore General Hospital.

In recent years, doctors have increasingly performed laparoscopic surgery, a minimally invasive procedure that reduces the physical burden on patients. The demand for surgical robots that support more precise procedures has grown, and medical professionals now use them across a wide range of specialties. Experts anticipate that the global market for surgical robots will continue to expand in response to growing worldwide demand.

Moreover, In August 2020, Medicaroid Corporation obtained manufacturing and marketing approval in Japan for the hinotori™, a made-in-Japan robotic-assisted surgery system. In December of that same year, Sysmex, the global distributor for hinotori™, began its sales in the domestic market. The medical specialities eligible for insurance reimbursement have expanded from urology in 2020 to include gastrointestinal surgery and gynaecology in 2022, and thoracic surgery (respiratory surgery) in 2024. As a result, the sales and installation of hinotori™ in Japan are progressing.

Also Read: Sysmex and QIAGEN Strengthen Partnership to Advance Genetic Testing

As a first step in global expansion Medicaroid obtained regulatory approval for hinotori™ in Singapore in September 2023 and Malaysia in August 2024.

Since obtaining regulatory approval in Singapore, Sysmex has been working together with Medicaroid to establish a sales and service structure in preparation for the first overseas market introduction.

Sysmex aims to contribute to a safer and more efficient surgical environment by providing hinotori™, which helps reduce the physical burden on patients. Through this, they strive to enhance the healthcare journey for individuals.